COMMUNIQUÉS West-GlobeNewswire

PrimeBiome Reviews Consumer Reports: Critical Complaints & Customer Reviews Exposed!
07/05/2025
ANCHORAGE, Alaska, May 07, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is a natural skin and gut health formula that has been gaining immense popularity in the market. As per the claims of the manufacturers, this formula is [...]
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
07/05/2025
First results of SCENESSE® study expected in 2H 2026 Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved Randomised trial, 20-week treatment protocol [...]
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
07/05/2025
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and [...]
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
07/05/2025
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform [...]
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
06/05/2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated [...]
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra [...]
Standard BioTools Reports First Quarter 2025 Financial Results
06/05/2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. [...]
Voyager Reports First Quarter 2025 Financial and Operating Results
06/05/2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on [...]
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/05/2025
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
06/05/2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
WW International, Inc. Announces First Quarter 2025 Results
06/05/2025
Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical Subscribers Revenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 [...]
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
06/05/2025
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter [...]
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
06/05/2025
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations [...]
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
06/05/2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin ( [...]
Amwell makes grant to new employee under inducement plan
06/05/2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to [...]
InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025
06/05/2025
DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
89bio to Participate in Upcoming Investor Conferences
06/05/2025
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, [...]
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
06/05/2025
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year [...]

Pages